Please login to the form below

Not currently logged in
Email:
Password:

People, February, 2012

Recent high-profile moves in the pharmaceutical and healthcare industries
Mover of the month is Mark Trudeau, who has become president of Covidien

Mover of the month

  
 Mark Trudeau, Covidien

Mark Trudeau, president and CEO of Bayer Healthcare Pharmaceuticals US region, has become president of Covidien's pharmaceutical segment and senior vice president of the company. He replaces Matthew Harbaugh, chief financial officer, pharmaceuticals, who was interim president following Timothy Wright's resignation in November 2010. Trudeau will oversee plans to make Covidien's pharmaceutical division into a standalone company. Covidien has headquarters in Ireland and the US and is ranked among the top 10 generic drug manufacturers in the US. Trudeau has spent over 25 years in the pharmaceutical industry, including several years at Bristol-Myers Squibb. He also worked at Eli Lilly & Company and Abbott Laboratories.
 


 

Boehringer Ingelheim has promoted Paul Fonteyne to president and CEO of its US operations. He takes over from J Martin Carroll, who remains with the company in a corporate strategy and development role. Fonteyne was formerly corporate senior vice president with responsibility for leading the global marketing strategy supporting Boehringer's prescription medicines business.
 

 

Paul Fonteyne, Boehringer Ingelheim



Mike Crooks, Astellas  

Astellas Pharma Europe has promoted Mike Crooks to general manager of its UK affiliate, Astellas Pharma Ltd. He joined Astellas Pharma Ltd in December 2007 as marketing director and was appointed sales and marketing director for specialist brands in 2010. Crooks has spent more than 30 years in the pharmaceutical industry, starting as a sales representative with Ciba. He subsequently held positions at Novartis and Zeneca. Prior to joining Astellas's UK operations he served at Novo Nordisk as marketing and sales director: diabetes, Northern Europe. He replaces Amit Makwana, who died unexpectedly in June 2011.

GlaxoSmithKline (GSK) has appointed Dr Richard Jones to its Rare Disease Unit as global commercial leader, in a role that will see him guide commercial strategy across CNS, neuromuscular disorders, rare malignancies and haematology franchises. He joins from Genzyme, where he served as director, EMEA oncology and transplant. Prior to Genzyme, he worked at Shire and at the MSI consultancy.



 Richard Jones, GlaxoSmithKline



Anders Ekblom, Briggs Morrison, AstraZeneca

AstraZeneca (AZ) has set up a new team in its R&D division to establish partnership deals with leading public and private bodies, named the Science and Technology Integration Office. Dr Anders Ekblom (left), one of its most senior R&D executives, will lead it. Formerly executive vice president of Global Medicines Development (GMD), he is also CEO of AZ Sweden, a role in which he will continue. Dr Ekblom's former GMD role is taken by Dr Briggs Morrison, who joins the company from Pfizer. Dr Morrison joined Pfizer in 2007 as chief of clinical development and prior to that he was senior vice president of research at Merck & Co.



Dr David Gillen has been named UK and Ireland medical director at Celgene. He joins from Gilead Sciences where he was head of International Medical Affairs from 2010. Gillen's prior roles include UK medical director at Pfizer, a position he held from 2007 until 2009 when he was appointed head of medical for the Pfizer Primary Care Business Unit covering Europe, Canada, Australia and New Zealand. He worked as a physician in the UK for seven years before entering the pharma industry (UKCRC).


David Gillen, Celgene

 

 


Michele Antonelli, UCB

UCB has appointed Mark Bodmer as head of immunology in its New Medicines research and early development division. The company has also promoted Michele Antonelli to managing director of UCB France. He previously worked as head of the company's technical operations and quality team, a position that will now be filled by UCB's chief operating officer Mark McDade. Bodmer joins the Belgium-based pharma company from GlaxoSmithKline (GSK), where he was senior VP of immuno-inflammation, medicines, discovery and development. In his new role Bodmer will be based at UCB's UK research site. He will sit on the New Medicines leadership team and report to the division's president Ismail Kola. Bodmer's appointment is the third to the team, following those of Duncan McHale as head of global exploratory development and Peter Theil as head of non-clinical development.

Dr Richard Barker OBE, former director general of the Association of the British Pharmaceutical Industry (ABPI), has been appointed senior adviser at Aegate, as well as being elected to the board of directors at Celgene. Aegate has also appointed Michael Peace as its new CEO. He is the former head of Asia for Thomson Reuters' financial markets business. Barker spent almost seven years in charge of the ABPI until May 2011. He is also director of the Oxford Centre for Accelerating Medical Innovations. Previous positions include chief executive of Chiron Diagnostics and general manager of IBM's Worldwide Healthcare Solutions business. He was also on the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Peace replaces Gary Noon, who spent six years in charge of the company. Peace has built a number of financial information and trading businesses in Asia, the US and Europe.



 Richard Barker, Celgene




Ian Smith, Glide Pharma

Founder of drug delivery company Meridica, Dr Ian Smith, has been appointed CEO of UK speciality firm, Glide Pharma. Dr Smith, who was also head of inhalation and device product development groups at both Glaxo and Pfizer, takes over from James Otter, who remains on the board of directors. Gaining his PhD in 1972, Smith was most recently founder and director of industry consultancy firm H12 Consulting. From 2004 to 2010, he was head of Inhalation and Devices Centre of Emphasis at Pfizer R&D. He held a similar role at Glaxo as head, inhalation product development and pharmaceutical technology. In 2001, Dr Smith also set up drug delivery firm Meridica, taking the CEO role. The company was acquired by Pfizer in 2004, with a valuation of $140m.

The interim chief executive of Eucomed is Luciano Cattani, who will lead the European medical technology organisation following the departure of John Wilkinson. The body is set to unite with the European Diagnostic Manufacturers Association under a single chief executive. Wilkinson spent three years in charge of Eucomed. Cattani has held positions in general management at Pfizer, as well as serving as president EMEA and group president international at medical technology company Stryker.


 Luciano Cattani, Eucomed



 

Michael A Marletta, Scripps Research Institute

Dr Richard A Lerner has left his position as president and CEO of the Scripps Research Institute following 20 years in charge. He will be replaced by Dr Michael A Marletta, who comes from the University of California, Berkeley, US, where he served as chair of the department of chemistry as well as holding several other biochemistry-related roles. Lerner was elected the non-profit organisation's first president in 1991. He had been head of the Research Institute of Scripps Clinic since 1987. Marletta is a former recipient of the prestigious MacArthur Fellowship and is described as a 'pioneer' in discovering the role of nitric oxide in communication between cells.

Octapharma USA has appointed David Holliday, former VP global marketing operations and haemophilia at Baxter Bioscience, as VP commercial development. Holliday will lead US product marketing, sales and commercial activities and co-ordination with global portfolio development initiatives at the US affiliate of Swiss-headquartered Octapharma AG. He spent eight years at Baxter and previously worked at Novartis and Ciba-Geigy Pharmaceuticals.





 David Holliday, Octapharma



New president and CEO of Teva Europe is Dr Rob Koremans, former senior vice president, generic strategy and development, at Sanofi. Koremans takes over the role in March 2012 from Dr Gerard van Odijk who has held both positions for six years. Van Odijk will remain at the company for the remainder of 2012 to help with the transition. Prior to his position at Sanofi, Koremans was CEO at Zentiva, Sanofi's European generics business. He has also been CEO of Cryo-Save and vice president, Europe, of the Serono Group.

The Spanish government has made five appointments to its ministry of health, social services and equality. The appointments, made by Mariano Rajoy's ruling People's Party, include that of Pilar Farjas Abbey as new general secretary of health; Juan Manuel Moreno Bonilla as secretary of state for social services and equality and María Jesús Fraile Fabra, as undersecretary of the ministry. Maria Teresa Bernedo Arzak is director of cabinet minister, while Blanca Hernandez Oliver is new delegate of the government to gender violence. The appointments were presided over by minister of health, social services and equality, Ana Mato.

Dr Roy Baynes has been appointed senior VP, oncology therapeutics of US biopharma Gilead. His appointment comes after 10 years at Amgen where he served as VP, global development and therapeutic area head of haematology and oncology. Baynes will report to Dr Norbert Bischofberger, executive VP, R&D and chief scientific officer. Prior to his role at Amgen, Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit.

Jeffrey Albers, former vice president of Genzyme/Sanofi's US haematology and oncology business, has been appointed president of the newly formed US division of Norwegian firm Algeta. He will manage the formation of a US-based sales force and marketing and medical affairs team ahead of the launch of prostate cancer treatment Alpharadin (radium-223 chloride). Albers spent seven years at Genzyme, before and after its acquisition by Sanofi, overseeing the launch of immunostimulant Mozobil (plerixafor injection) and the acquisitions of cancer treatments Campath and Leukine from Bayer.

Glenn Begley, former president and global head of haematology and oncology research at Amgen, has been appointed senior clinical advisor and non-executive director at Oxford BioTherapeutics. He spent over ten years leading Amgen's cancer strategy, overseeing the progression of 24 molecules into clinical development. In his new role, he will advance the company's pipeline of oncology antibody-based drugs into clinical development.



Related links

FAQ: How do I get my move listed

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics